Document Detail


Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection?
MedLine Citation:
PMID:  22724482     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is strong epidemiological evidence that patients with diabetes have a lower incidence of abdominal aortic aneurysm. The precise mechanism of this negative association is unknown. Whilst a number of studies have supported the hypothesis that protection is a function of diabetes-mediated changes in the vascular extracellular matrix biology, there is also support for the idea that the treatment regimens used in diabetes may afford protection against AAA. In particular the pleiotropic drug family, the thiazolidinediones have been examined as candidates to ameliorate aneurysm formation. Both the thiazolidinediones, and the structurally related family, fibrates, have been shown to have anti-inflammatory and antioxidative effects, in addition to ability to modulatate glucose and lipid homeostasis. In this brief review we present the current data exploring the use of thiazolidinediones in experimental aneurysm development. Despite the fact that both thiazolidinediones Rosiglitazone and Pioglitazone are no longer prescribed in Europe and the US, they have provided important insights into the mechanism of action, and the application of other pleiotropic drugs in the treatment of AAA. One such pleiotropic drug is high-density lipoproteins (HDLs), which have been shown to have a broad spectrum of effects, including activation of PPARs, which may favour their use as a new drug target for protection against AAA development.
Authors:
Evelyn Torsney; Grisha Pirianov; Gillian W Cockerill
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  11     ISSN:  1875-6212     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-05-08     Completed Date:  2013-12-10     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  293-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Aortic Aneurysm, Abdominal / epidemiology,  prevention & control*
Diabetes Mellitus / drug therapy,  epidemiology*
Humans
Hypoglycemic Agents / pharmacology
Lipoproteins, HDL / metabolism
Molecular Targeted Therapy
Peroxisome Proliferator-Activated Receptors / drug effects,  metabolism
Risk Factors
Thiazolidinediones / pharmacology*
Grant Support
ID/Acronym/Agency:
PG/10/001/28098//British Heart Foundation; PG10/01//British Heart Foundation
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Lipoproteins, HDL; 0/Peroxisome Proliferator-Activated Receptors; 0/Thiazolidinediones; 122320-73-4/rosiglitazone; X4OV71U42S/pioglitazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antimicrobial Treatment to Impair Expansion of Abdominal Aortic Aneurysm (AAA): A Systematic Review ...
Next Document:  Statin Use in Aortic Aneurismal Disease to Prevent Progression and Cardiovascular Events: Review of ...